Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash from Financing Activities (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Cash from Financing Activities for 14 consecutive years, with -$640000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 312.9% to -$640000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.9 million through Dec 2025, down 1774.84% year-over-year, with the annual reading at -$2.9 million for FY2025, 1774.84% down from the prior year.
  • Cash from Financing Activities hit -$640000.0 in Q4 2025 for Vanda Pharmaceuticals, down from -$517000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $1.8 million in Q1 2021 to a low of -$1.3 million in Q1 2025.
  • Historically, Cash from Financing Activities has averaged $101916.7 across 4 years, with a median of $64500.0 in 2022.
  • Biggest five-year swings in Cash from Financing Activities: surged 286.01% in 2021 and later crashed 312.9% in 2025.
  • Year by year, Cash from Financing Activities stood at $1.0 million in 2021, then plummeted by 41.88% to $605000.0 in 2022, then plummeted by 125.62% to -$155000.0 in 2024, then plummeted by 312.9% to -$640000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for VNDA at -$640000.0 in Q4 2025, -$517000.0 in Q3 2025, and -$425000.0 in Q2 2025.